Viral evolution of hepatitis C in injection drug users

Journal of Viral Hepatitis

Volumn 12, Issue 6, 2005, Pages 574-583

  Dove, Lorna ^a,b,c   Phung, Yume ^a,d   Bzowej, Natalie ^a,d   Kim, M ^a   Monto, A ^a   Wright, T L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Injection drug users; Natural history; Quasispecies

Indexed keywords

VIRUS RNA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG ABUSE; DRUG USE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNITY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SELF INJECTION; SUPERINFECTION; VIROLOGY; VIRUS GENOME; VIRUS STRAIN;

ADULT; AGED; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETERODUPLEX ANALYSIS; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; POLYMERASE CHAIN REACTION; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL ENVELOPE PROTEINS;

EID: 27444431514     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00640.x     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(RR-19): 1-39.
2. Alter M, Mast E. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-455.
3. Lorvick J, Krai A, K Seal K, Gee L, Edlin B. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91(1): 46-47.
4. Tong M, el-Farra N. Clinical sequelae of hepatitis C infection from injection drug use. West J Med 1996; 164(5): 399-404.
5. Thomas D, Astemborski J, Rai R et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284(4): 450-456.
6. Rai R, Wilson L, Astemborski J et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002; 35(5): 1247-1255.
7. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34(2): 283-287.
8. Choo Q, Quo G, Ralston R. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-1298.
9. Simmonds P, Alberti A, Alter H et al. A proposed system for the nomenclature of hepatitis C virus genotypes. Hepatology 1994; 19(5): 1321-1324.
10. Chazouilleres O, Kim M, Combs C et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106(4): 994-999.
11. Weiner A, Grauer M, Rosenblatt J. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842-848.
12. Delwart E, Shapaer E, Louwagie J et al. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 1993; 262: 1257-1261.
13. Pessoa M, Bzowej N, Berenguer M et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30(6): 1513-1520.
14. Thompson J, Higgins D, Gibson T. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22(22): 4673-4680.
15. Felsenstein J. Evolutionary trees from DNA sequences: a maximum likelihood approach. J Mol Evol 1981; 17(6): 368-376.
16. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985; 39(4): 783-791.
17. Farci P, Alter H, Govomdarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 138-140.
18. Farci P, Purcell R. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20(1): 103-126.
19. Allain JP, Dong Y, Vandamme A, Moulton V, Salemi M. Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J Virol 2000; 74(6): 2541-2549.
20. Thorpe L, Bailey S, Huo D, Monterroso E, Quellet L. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr 2001; 27(1): 71-78.
21. Hagan H, Thiede H, Weiss N, Hopkins S, Duchin J, Alexander E. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91(1): 42-46.
22. Vargas H, Laskus T, Wang L et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus infected grafts. Gastroenterology 1999; 117(1): 149-153.
23. Hassoba H, Bzowej N, Berenguer M et al. Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection [In Process Citation]. J Hepatol 1999; 31(4): 618-627.
24. Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288(5464): 339-344.
25. Cabot B, Martell M, Esteban J et al. Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J Virol 2000; 74(2): 805-811.
26. Ompad D, Fuller C, Vlahov D, Thomas C, Strathdee S. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clin Infect Dis 2002; 35(7): 783-788.